SC
VVOS icon

Stephens Consulting’s Vivos Therapeutics VVOS Stock Holding History

Stephens Consulting’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-60
Closed -$512 – 532
2023
Q1 		$512 Hold
60
– – ﹤0.01% 503
2022
Q4 		$603 Hold
60
– – ﹤0.01% 474
2022
Q3 		$975 Hold
60
– – ﹤0.01% 523
2022
Q2 		$1.94K Hold
60
– – ﹤0.01% 479
2022
Q1 		$4.02K Sell
60
-60
-50% -$3.92K ﹤0.01% 460
2021
Q4 		$6.75K Buy
+120
New +$9.66K 0.01% 444

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Stephens Consulting's VVOS Position: Q2 2023 in Review

Stephens Consulting sold out of Vivos Therapeutics (VVOS) in Q2 2023, closing a stake of 60 shares — an estimated $512 sold.

Stephens Consulting first reported a position in VVOS in Q4 2021 and held it in 6 quarters. The position peaked at $6.75K in Q4 2021. 30 funds tracked by Wall St. Rank hold VVOS as of Q2 2023.

  • Stephens Consulting reported no remaining Vivos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Stephens Consulting sold 60 Vivos Therapeutics shares in Q2 2023, an estimated $512.
  • Stephens Consulting first reported a position in Vivos Therapeutics in Q4 2021 and held it in 6 quarters.
  • Stephens Consulting's Vivos Therapeutics position peaked at $6.75K in Q4 2021.
  • 30 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2023.

Based on Stephens Consulting's 13F filing for Q2 2023, filed 21 Jul 2023.